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Abstract 
Background and aims: MHC class I polypeptide-related chain A (MICA) molecule is induced in response to viral 
infection, various types of stress, such as endoplasmic reticulum stress, and ischemia or/and reperfusion, by which 
MICA was shed from the cell surface into the extracellular domain, generating a soluble form (sMICA). In the present 
study, we designed to investigate the serum sMICA level in patients with AMI and determine whether sMICA could be 
an early biomarker for diagnosis of AMI.
Methods: There were 103 patients who presented with first-time AMI that was assessed after the incident. The con-
trol group consisted of 103 healthy volunteers. Serum levels of sMICA and Troponin T were detected by the specific 
ELISA kits.
Results: Serum levels of sMICA reach the peaks [(1.34 ± .18 and 1.72 ± .20)n/l] at 6–12 h and serum levels of cTnT 
reach the peaks [(1.16 ± .28 and 1.14 ± .34)n/l] at 12–24 h. Both of them were significantly higher than the healthy 
controls [(.168 ± .014) n/l, p = .000] for sMICA and [(.13 ± .06) n/l, p = .000] for Troponin T (cTnT). sMICA is more sensi-
tive in the early diagnosis of AMI than cTnT. The combined ROC analysis revealed an AUC value of .78 (95 % CI .69–.83) 
in discriminating AMI patients from healthy controls.
Conclusions: We have detected high levels of sMICA in patients with AMI. Elevated serum sMICA may be a novel 
biomarker for the early detection of myocardial injury in humans.
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Background
Coronary artery disease (CAD) and acute myocar-
dial infarction (AMI) are the leading causes of death in 
developed and developing countries [1]. AMI accounts 
for most of the mortality due to CAD. Cardiac myo-
globin and creatine kinase-MB are used as biomarkers 
for diagnosing AMI [2], and plasma cTnI is widely used 
in clinical practice as the gold standard for diagnosing 
AMI [3]. However, elevated plasma cTnI was not only 
observed in certain cardiac ischemic injury, but also in 
some other diseases, such as severe heart failure, atrial 
fibrillation, chronic kidney disease, severe sepsis, septic 
shock, etc. [4–6]. Circulating biomarkers of myocardial 
damage, especially cardiac specific troponin, have facili-
tated the early diagnosis of AMI, maximizing the benefits 
of revascularization therapy. In AMI patients, troponin 
levels increase as early as 6 h (h) after the onset of chest 
pain. However, due to the relative delay in the timing of 
the release of troponin, it is necessary to find novel and 
effective biomarkers for the early and accurate diagnosis 
of AMI [7].
The non-classical major histocompatibility complex 
class I (MHCI) molecule A (MICA) has a molecular 
structure similar to that of the classical MHCI molecules 
[8]. MICA is a natural ligand for the activating receptor 
natural killer group 2, member D (NKG2D) expressed 
on the surface of natural killer (NK) cells. The binding of 
MICA to NKG2D triggers a cascade of signal transduc-
tion events that activate NK cells to release cytotoxic 
molecules and, subsequently, cause NK cells to identify 
and lyse target cells. Many malignant carcinoma cells 
express high levels of MICA on their surface, making 
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Under the physiologic conditions, MICA is only 
expressed in epithelial cells of the gastrointestinal tract 
and is only present at very low levels in most normal cells 
and tissues. However, it is activated by a variety of stim-
uli, such as endoplasmic reticulum stress, and ischemia 
or/and reperfusion [10–12]. Previous studies suggest 
that in addition to expressing membrane bound MICA, 
stress-inducible tissues MICA also have a mechanism to 
shed MICA from the cell surface into the extracellular 
domain, generating a soluble form (sMICA) [10].
In the present study, we investigate whether sMICA 
was elevated in patients with AMI. Then, we assess the 
clinical significance of sMICA level in patients with AMI. 
This is the first time in literature to investigate the clinical 
significance of sMICA in AMI.
Methods
Ethics statement
Experiments were conducted according to the Declara-
tion of Helsinki. This study was supported and approved 
by the Ethics Committee of Yishui Central Hospital. 
All participants formally consented to participate in all 
stages of the study.
Study population
Patients >18  years of age presenting to the emergency 
department with symptoms suggestive of AMI with an 
onset or peak within the last 24 h were recruited after pro-
viding written informed consent. 103 patients with AIM 
were enrolled. The clinical characteristics of all patients 
are given in Table 1. All the AMI patients were diagnosed 
according to the international criteria. Patients with previ-
ous MI or percutaneous coronary intervention (PCI), any 
chronic peritoneal or hemodialysis, acute or chronic infec-
tion, significant hepatic dysfunction, kidney failure (glo-
merular filtration rate (GFR) < 15 mL/min/1.73 m2 or on 
dialysis), or known or treated malignancies were excluded. 
103 healthy adult volunteers (normal ECG and no history 
of cardiovascular diseases, the same exclusion criteria) were 
enrolled as controls. All controls, who had the same exclu-
sion criteria and no history of any cardiovascular disease, 
came from the medical examination center of the Yishui 
Central Hospital of Linyi. Full blood count and routine bio-
chemistry indices were determined invenous blood. Cre-
atine kinase-MB (CK-MB) and cardiac specific troponin T 
(TnT) were measured in serum immediately after arrival at 
the hospital as markers of myocardial damage.
Routine clinical assessment
Complete blood count, including white blood cell 
(WBC), hemoglobin (Hb), and chemical profiles, includ-
ing blood urea nitrogen (BUN), creatinine (Cr), uric acid, 
total cholesterol (TC), triglyceride (TG), high-density 
lipoprotein cholesterol (HDL), and low-density lipopro-
tein cholesterol (LDL) were checked by venous blood 
sampling. The initial cardiac enzymes, including CK-MB 
and cardiac specific troponin T (cTnT), were measured 
on just after arrival at the hospital as markers of myo-
cardial damage using venous blood. The CK-MB was 
checked every 8  h. The cTnT was then checked as the 
time of chest pain depicted in Table 2.
Serum sMICA measurements
Initial serum sMICA was measured on just after arrival at 
the hospital, and then sMICA was checked as the time of 
chest pain depicted in Table 1. Briefly, 5 mL venous blood 
samples of patients with AMI and controls were collected 
in EDTA anticoagulant tubes at admission. Samples were 
centrifuged at 3000×g for 10  min at 4  °C, and then the 
supernatant was isolated and collected. Serum sMICA 
levels were measured using a commercially available kit 
(Human sMICA ELISA Kit). The intra-assay precision, 
expressed as coefficients of variation, was 4.6–8.4 %; the 
inter-assay precision was 5.3–8.6  %, and the sensitivity 
was <7.4 ng/l. All assays were performed in duplicate.
Statistical analysis
Statistical treatment was performed using the SPSS 17.0 
software (Chicago, IL, USA). Continuous variables were 
compared with the use of the Mann–Whitney-test and 
t test, as appropriate, and categorical variables with the 
use of the Pearson’s Chi-square test. Receiver operating 
characteristic (ROC) curves were constructed to assess 
the sensitivity and specificity of sMICA measurements 
Table 1 Baseline characteristics of the patients
Characteristic Control AMI p value
Age (years) 60 ± 12.2 61.3 ± 11.4 .54
Sex: male/female 55/48 60/43 .36
BMI (kg/m2) 23.6 ± 4.1 24.7 ± 4.3 .518
Waist (cm) 93.4 ± 12.4 94.2 ± 13.1 .83
SBP (mm Hg) 119.3 ± 21.4 132.4 ± 22.7 .428
Body mass index (kg/m2) 67.5 ± 13.3 68.8 ± 13.6 .46
SBP (mm Hg) 119.3 ± 21.4 132.4 ± 22.7 .236
DBP (mm Hg) 76.3 ± 12.2 88.4 ± 11.5 .614
WBC (x103/ul) 6.36 ± 1.23 11.15 ± 2.17 <.001
HB (g/dl) 13.1 ± 1.56 14.4 ± 1.42 .184
TG (mmol/L) 1.32 ± .75 1.53 ± .84 .165
Cholesterol (mg/dL) 166.5 ± 32.5 168.7 ± 34.4 .546
FBS (mg/dL) 86.5 ± 15.4 97.2 ± 14.6 .176
HDL (mg/dL) 46.8 ± 13.4 41.5 ± 11.0 .342
CK-MB (U/L) 18.27 ± 7.43 46.1 ± 42.3 .001
Cardiac troponin T (ng/l) .13 ± .06 1.31 ± .14 .000
sMICA (ng/l) .128 ± .014 1.72 ± .23 .000
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obtained to compare its ability to diagnose AMI. Multiple 
logistic regression analysis was carried out for evaluating 
the combined diagnostic accuracy of circulating sMICA. 
All hypothesis testing was two-tailed, and P values of less 
than .05 were considered to indicate statistical signifi-
cance without adjustments for multiple testing.
Results
Circulating CK‑MB,Troponin T, and sMICA levels in AMI 
patients
We detected the circulating Troponin T (cTnT) value in 
AMI. The mean value was [1.31 ±  .14] ng/l, which was 
significantly higher than the controls [(.13  ±  .06) ng/l] 
(p = .000).Circulating CK-MB and sMICA levels in AMI 
patients was about [(46.1 ± 42.3)U/L] and [(1.72 ±  .23] 
ng/l], which was significantly higher than the controls 
[(18.27  ±  7.43) U/L] (p  <  .01) and [(.128  ±  .014] ng/l] 
(p = .000). Among 103 patients with AMI, the basic clini-
cal characteristics of the patients in this study are shown 
in Table 1.
sMICA is more sensitive than cTnT in the early diagnosis 
of AMI
We divided the AMI patients into several groups 
according to the time of chest pain in Table  2. Circu-
lating cTnT and TGF-β1 values was detected at 0, 0–3, 
3–6, 6–12, and 12–24  h after arrival at the hospital. 
Because the circulating CK-MB is less sensitive than 
cTnT, so we did not detected it for further investigation. 
As shown in Table 2, circulating cTnT was significantly 
enhanced when suffered from chest pain for 3–6 h and 
reached the peak levels at 12–24  h. However, circulat-
ing sMICA was significantly enhanced when suffered 
from chest pain for 3 h, and reached the peak levels at 
6–12 h, then declined rapidly from 12 h, and restored to 
the normal levels at 24 h. Although cTnT was enhanced 
when suffered from chest pain for 0–3  h (.26  ±  .05), 
there is not significantly different compared to the 
control (.12  ±  .08) (p  >  .05). However, sMICA value 
was significantly enhanced when suffered from chest 
pain for 0–3 h (.937 ±  .11), there is significantly differ-
ent compared to the control (.172 ±  .02) (p < .05). We, 
therefore, suggested that sMICA is more sensitive in the 
early diagnosis of AMI.
Circulating sMICA levels as predictors of AMI
Figure  1a shows analysis according to the timing of the 
blood sample from outset on symptoms. TGF-β1 levels 
peaked at 3–6 h and TnT at 12–24 h. To further evalu-
ate the predictive power of serum sMICA for AMI, ROC 
curve and areas under ROC curve (AUC) analyses were 
performed. As shown in Fig.  1b, the AUC of sMICA in 
AMI patients was .78 (95 % CI .69–.83) (p < .001). ROC 
curve analysis of sMICA exhibited strong differentiation 
power between AMI patients and healthy controls during 
the early phase of AMI.
Discussion
Previous studies have found that MICA shedding is con-
sidered a principal mechanism of tumor cells to escape 
from NKG2D-mediated immunosurveillance in humans. 
MICA shedding not only results in a reduction of MICA 
surface density on tumor cells but also generates sMICA, 
which was shown to systemically down-regulate NKG2D 
on cytotoxic effector cells and to promote expansion of 
immunosuppressive, intratumoral CD4+  NKG2D+  T 
cells [13]. Recently, it has been found that MICA could 
be activated in the normal tissues by a variety of stim-
uli, such as endoplasmic reticulum stress, γ-irradiation, 
commonly used chemotherapeutic drugs, and ischemia/
reperfusion-induced tissue injury [10–12]. The acti-
vated MICA could also shed to the MICA, and generate 
Table 2 Circulating cTnT and sMICA levels (ng/l) in AMI
Vs control value: *p = .000; #p = .000
Time of chest pain Time of arrival at the hospital
0 h 3 h 6 h 12 h 24 h
cTnT sMICA cTnT sMICA cTnT sMICA cTnT sMICA cTnT sMICA
0–1 h (n = 4) .15 ± .07 .19 ± .13 .26 ± .05 1.14 ± .02# .62 ± .07 1.72 ± .67# 1.36 ± .28* 1.24 ± .18# 1.24 ± .34* .46 ± .024
1–2 h (n = 7) .18 ± .12 .34 ± .08 .31 ± .06 1.63 ± .25# .61 ± .12* 1.52 ± .17# 1.14 ± .26* .78 ± .07 1.12 ± .29* .212 ± .04
2–3 h (n = 10) .21 ± .07 .84 ± .09 .52 ± .15* 1.71 ± .06# .89 ± .32* 1.17 ± .06# 1.25 ± .27* .6 ± .05 1.08 ± .26* .197 ± .048
3–4 h (n = 23) .28 ± .06 1.012 ± .11# .57 ± .13* 1.42 ± .11# 1.08 ± .27* .92 ± .07# 1.33 ± .32* .56 ± .05 1.16 ± .28* .173 ± .048
4–5 h (n = 20) .36 ± .09 1.528 ± .1# .75 ± .23* 1.22 ± .14# 1.13 ± .24* .71 ± .07 1.25 ± .26* .292 ± .04 1.04 ± .21* .18 ± .04
5–6 h (n = 16) .53 ± .12* 1.64 ± .16# .92 ± .17* 1.02 ± .16# 1.17 ± .26* .57 ± .065 1.19 ± .27* .27 ± .032 1.12 ± .23* .199 ± .04
6–12 h (n = 19) .94 ± .35* 1.20 ± .10# 1.13 ± .25* .68 ± .09 1.09 ± .23* .376 ± .09 1.06 ± .24* .279 ± .04 .96 ± .21* .19 ± .04
12–24 h (n = 4) 1.26 ± 1.16* .386 ± .08 1.16 ± .14* .255 ± .05 1.15 ± .18* .24 ± .05 1.07 ± .20* .29 ± .05 .97 ± .23* .18 ± .05
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sMICA [11]. However, the function of sMICA generated 
in the stressed tissues is not clear.
Smith et  al. [14] have reported that 15.8  % of cardiac 
allograft recipients produced sMICA, sMICA do not 
adversely affect the outcome of cardiac transplantation. 
However, Kauke et  al. have found that sMICA may be 
related to adverse outcome after heart transplantation. 
Post-transplantation monitoring of sMICA antibodies 
could identify patients with an increased risk for acute 
rejection and vasculopathy [15]. Zou et  al. have found 
that presensitization of kidney-transplant recipients 
against  MICA  antigens is associated with an increased 
frequency of graft loss and might contribute to allograft 
loss among recipients who are well matched for HLA 
[16].
In this study, serum sMICA was visibly increased in 103 
AMI patients. The ROC analyses showed that the sMICA 
might be suitable diagnostic markers of AMI. In addition, 
we found that sMICA levels was significantly increased 
at 3 h, and peak at 12 h, and returned to the normal level 
at 24 h. However, Troponin levels increased at 6 h, peak 
at 12 h, and stay elevated after 24 h. We, therefore, sug-
gested that sMICA could be an early marker for the diag-
nosis for AMI.
Although sMICA is activated in AMI, the function 
and mechanisms of sMICA are poorly understood. 
Experimental studies suggest that increased sMICA or 
MICA was an indicator of poor prognosis in cancer dis-
eases [17–19]. Therefore, understanding the signaling 
mechanisms responsible for sMICA-mediated effects is 
important to design novel therapeutic strategies, target-
ing the sMICA signaling cascade in the infarcted and 
remodeling heart.
Conclusion
In conclusion, this study has shown elevated sMICA 
concentrations in patients with AMI. Elevated sMICA in 
plasma may be a novel biomarker for the early detection 
of myocardial injury in humans. However, a large-scale 
prospective cohort study is necessary to determine the 
potential casual relationship between sMICA and AMI.
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